QA 102
Alternative Names: QA-102Latest Information Update: 12 May 2026
At a glance
- Originator Zhuhai Qiwei Biotechnology
- Developer Smilebiotek Zhuhai Limited
- Class Eye disorder therapies; Small molecules
- Mechanism of Action Bacterial growth inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Dry age-related macular degeneration
Most Recent Events
- 06 May 2026 Efficacy data from a phase II trial in Wet age related macular degeneration released by MingMed Biotechnology
- 12 Nov 2024 Smilebiotek Zhuhai Limited completes a phase-II trial in Dry age-related macular degeneration in USA (PO) (NCT05536752)
- 13 Sep 2022 Zhuhai Qiwei Biotechnology plans a phase II AMEND trial for Dry age-related macular degeneration (In volunteers, In the elderly) in USA (PO, Capsules), in September 2022 (NCT05536752)